Dr. Schuchter is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
South Pavilion
3rd Floor, Suite 3-300
Philadelphia, PA 19104Phone+1 215-662-7908Fax+1 215-662-2432- Is this information wrong?
Summary
- Dr. Lynn Schuchter is an oncologist in Haverford, PA and is affiliated with multiple hospitals in the area, including Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, and UPMC Presbyterian. She received her medical degree from Chicago Medical School at Rosalind Franklin University and has been in practice 35 years. She specializes in hematologic oncology and melanoma and is experienced in sarcomas, melanoma and cutaneous malignancies, and general medical oncology.
Education & Training
- Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1986 - 1989
- Michael Reese Hospital and Medical CenterResidency, Internal Medicine, 1985 - 1986
- Michael Reese Hospital and Medical CenterResidency, Internal Medicine, 1982 - 1984
- Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 1982
Certifications & Licensure
- PA State Medical License 1989 - 2024
- MD State Medical License 1986 - 1989
- IL State Medical License 1982 - 1987
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2008-2014
- Philadelphia Magazine Castle Connolly, 2005-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Join now to see all
Clinical Trials
- Tretinoin With or Without Fenretinide in Treating Patients With Dysplastic Nevus Syndrome Start of enrollment: 1999 Feb 23
- Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma Start of enrollment: 2011 Nov 01
- Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1) Start of enrollment: 2014 Jan 24
Publications & Presentations
PubMed
- FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma.Thomas M Anderson, Bryan H Chang, Alexander C Huang, Xiaowei Xu, Daniel Yoon, Catherine G Shang, Rosemarie Mick, Erin Schubert, Suzanne McGettigan, Kristin Kreider, We...> ;Clinical Cancer Research. 2024 Jan 24
- 2 citationsA Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progres...Weiss, S., Sznol, M., Shaheen, M., Berciano-Guerrero, M., Couselo, E., Rodríguez-Abreu, D., Boni, V., Schuchter, L., Gonzalez-Cao, M., Arance, A., Wei, W., Ganti, A., ...> ;Clinical Cancer Research. 2024 Jan 5
- Remote Patient-Reported Outcomes and Activity Monitoring to Improve Patient-Clinician Communication Regarding Symptoms and Functional Status: A Randomized Controlled T...Ravi B Parikh, Emily Schriver, William J Ferrell, Jonathan Wakim, Joelle Williamson, Neda Khan, Michael Kopinsky, Mohan Balachandran, Peter E Gabriel, Lynn M Schuchter...> ;JCO Oncology Practice. 2023 Dec 1
- Join now to see all
Journal Articles
- Effect of Integrating Machine Learning Mortality Estimates with Behavioral Nudges to Clinicians on Serious Illness Conversations Among Patients with CancerRavi B Parikh, Justin E Bekelman, Lynn M Schuchter, Lawrence N Shulman, Mitesh S Patel, JAMA Oncology
- Validation of a Machine Learning Algorithm to Predict 180-Day Mortality for Outpatients with CancerLawrence N Shulman, Lynn M Schuchter, Mitesh S Patel, Ravi B Parikh, JAMA Oncology
- Exosomal PD-L1 Contributes to Immunosuppression and Is Associated with Anti-PD-1 ResponseXiaowei Xu, Haidong Dong, Tara C Mitchell, Lynn M Schuchter, Alexander C Huang, Suzanne McGettigan, Wei Xu, Giorgos C Karakousis, Xiaoming Liu, Gordon Mills, Nature
- Join now to see all
Press Mentions
- A First-of-Its-Kind Opportunity to Integrate Training in Medical Oncology, Hematology, and Palliative CareJune 10th, 2022
- Penn Medicine’s Chief of Hematology-Oncology Named President-Elect of American Society of Clinical OncologyDecember 17th, 2021
- Cancer Care in Penn Medicine’s Pavilion: Reimagined, Revitalized, and InclusiveSeptember 30th, 2021
- Join now to see all
Grant Support
- Cellular Molecular Biologics In Clinical Cancer ResearchNational Cancer Institute2010–2011
- Targeted Therapy For MelanomaNational Cancer Institute2004–2008
- Targeted Therapy For MelanomaNational Cancer Institute2007
- Upcc #1698 Injections Of B7 1 In Patients W/ Metastatic MelanomaNational Center For Research Resources1999–2002
- Core--Clinical Research UnitNational Cancer Institute1996–2002
- Clinical Application Of Adenovirus-Transduced, B7-Expressing Breast Cancer CellsNational Cancer Institute1996–1998
- Phase II Study Of Bryostatin-1 In Patients With Metastatic MelanomaNational Center For Research Resources1996–1997
- Genetically-Engineered Vaccine For Melanoma PatientsNational Cancer Institute1995–1997
- Phase I Trial Of Ethyol And G-CSF With Dose Escalation Of Taxol In PatientsNational Center For Research Resources1996
- Evaluation Of Interleukin-4 Therapeutic And Biological ENational Cancer Institute1990
Professional Memberships
- Fellow
Hospital Affiliations
- Hospital of the University of PennsylvaniaPhiladelphia, Pennsylvania
- Penn Presbyterian Medical CenterPhiladelphia, Pennsylvania
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: